Epidermal Growth Factor Receptor (EGFR)
Showing 1 - 25 of >10,000
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in
Recruiting
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
-
Canton, OhioGabrail Cancer and Research Center
Jul 21, 2023
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)
Recruiting
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
-
Canton, OhioGabrail Cancer and Research Center
Jul 25, 2023
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer Trial (HER3-DXd)
Available
- Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
- (no location specified)
Oct 17, 2023
Non Small Cell Lung Cancer Trial in Durham (Atezolizumab, Bevacizumab)
Active, not recruiting
- Non Small Cell Lung Cancer
-
Durham, North CarolinaDuke University Medical Center
May 23, 2022
Observes Afatinib as First-line Treatment and Sequential Therapy
Active, not recruiting
- Non-squamous, Non-Small Cell Lung Cancer
-
Beijing, China
- +9 more
Jan 9, 2023
NSCLC Trial (Mobocertinib 160 mg)
Approved for marketing
- Carcinoma, Non-Small-Cell Lung
- Mobocertinib 160 mg
- (no location specified)
Sep 28, 2022
Real-world Data of Afatinib Treatment in First-line Setting and
Active, not recruiting
- Non-squamous, Non-Small Cell Lung Cancer
-
Tokyo, JapanNippon Boehringer Ingelheim Co., Ltd.
Jan 9, 2023
NSCLC Trial in Qingdao (Osimertinib Oral Tablet)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Osimertinib Oral Tablet
-
Qingdao, Shandong, ChinaQingdao Central Hospital, Qingdao Cancer Hospital
Nov 1, 2021
NSCLC Trial in Qingdao (osimertinib oral and bevazizumab intravenously)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- osimertinib oral and bevazizumab intravenously
-
Qingdao, Shandong, ChinaQingdao Central Hospital, Qingdao Cancer Hospital
Nov 1, 2021
NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- (no location specified)
Mar 27, 2023
Lung Cancer Trial in Houston (Ibrutinib)
Completed
- Lung Cancer
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 21, 2021
NSCLC (NSCLC) Trial (Dacomitinib+Anlotinib, Dacomitinib)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Feb 28, 2022
NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)
Not yet recruiting
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- (no location specified)
Aug 27, 2023
NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +6 more
- (no location specified)
Nov 7, 2023
Central Nervous System Metastatic EGFR Mutation Positive NSCLC
Not yet recruiting
- NSCLC
-
Changsha, Hunan, ChinaHunan Cancer hospital
Aug 6, 2023
NSCLC, EGF-R Positive NSCLC Trial in Shenyang (Icotinib, Cisplatin, Carboplatin)
Not yet recruiting
- NSCLC
- EGF-R Positive Non-Small Cell Lung Cancer
- Icotinib
- +3 more
-
Shenyang, Liaoning, ChinaLiaoning Cancer Hospital & Institute
Nov 28, 2021
NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)
Active, not recruiting
- NSCLC Stage IIIB
- +4 more
-
Hong Kong, Hong Kong
- +8 more
Jan 10, 2023
Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)
Recruiting
- Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
- Topical Timolol
-
Hong Kong, Hong KongQueen Mary Hospital
Nov 14, 2023
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer Trial in Buffalo, Cleveland (Cetuximab,
Completed
- Recurrent Colorectal Carcinoma
- +2 more
- Cetuximab
- +2 more
-
Buffalo, New York
- +1 more
Sep 29, 2022